Atipamezole Market by Application (Anti-Sedative and Others) and Route of Administration (Intravenous, Intramuscular, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025

Get 20% Free Customization In This Report

Pharmaceuticals	LI_183352	Pages: NA	May 2019 \| 1070 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Atipamezole is a synthetic alpha 2 adrenergic receptor antagonist drug, which reverses the effects of sedative and analgesic drugs such as medetomidine, xylazine, amitraz, and detomidine among others, in animals. In addition, it is used to treat amitraz and imidazoline decongestants toxicity in animals.

Reduction in sedative time of animals shortens the in-clinic stay, saves the time of the staff, reduces hospitalization costs, and reduces revisits of the animal owner. Furthermore, the rising pet ownership and increasing healthcare expenditure on animals are anticipated to fuel the market growth. However, adverse effects of atipamezole and stringent government regulations associated with the safety and efficacy of atipamezole is anticipated to hinder the market growth. For instance, atipamezole is not approved for use in cats in the U.S. Ongoing R&D activities on atipamezole is anticipated to provide opportunities for the market growth.

The market is segmented on the basis of application, route of administration, and geography. Based on application, the market is divided into anti-sedative and others (anti-analgesic and amitraz toxicity). By route of administration, the market is segmented into intravenous, intramuscular, and others (subcutaneous and intraperitoneal). Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

The study provides an in-depth analysis of the global atipamezole market with current trends and future estimations to elucidate investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
The report provides a quantitative analysis to help stakeholders capitalize on prevailing market opportunities from (2017-2023) in terms of value.
Extensive analysis of different segments helps understand various products of the market.
Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

Atipamezole Market Key Segment:

By Application

Anti-Sedative
Others

By Route of Administration

Intravenous
Intramuscular
Others

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
LAMEA
- Latin America
- The Middle East
- Africa

List of players profiled in the report

Pfizer Inc.
Orion Corporation
Alvetra & Werfft GmbH
CP Pharmaceuticals Ltd.
Sogeval Laboratories, Inc.
VetPharm, Inc.
Ceva Sant Animale S.A.
Dr. E. Graeub AG
A x ience SAS
Eli Lilly and Company

"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 ATIPAMEZOLE MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ANTI-SEDATIVE

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. OTHERS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 ATIPAMEZOLE MARKET, BY ROUTE OF ADMINISTRATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. INTRAVENOUS

5.2.1. Market size and forecast

5.3. INTRAMUSCULAR

5.3.1. Market size and forecast

5.4. OTHERS

5.4.1. Market size and forecast

Chapter: 6 ATIPAMEZOLE MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Atipamezole Market by Application
6.2.5. North America Atipamezole Market by Route of Administration

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Atipamezole Market by Application
6.3.5. Europe Atipamezole Market by Route of Administration

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Atipamezole Market by Application
6.4.5. Asia-Pacific Atipamezole Market by Route of Administration

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Latin America market size and forecast
6.5.3.2. Middle East market size and forecast
6.5.3.3. Africa market size and forecast

6.5.4. LAMEA Atipamezole Market by Application
6.5.5. LAMEA Atipamezole Market by Route of Administration

Chapter: 7 COMPANY PROFILES

7.1. PFIZER INC.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. ORION CORPORATION

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. ALVETRA & WERFFT GMBH

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. CP PHARMACEUTICALS LTD.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. SOGEVAL LABORATORIES, INC.

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. VETPHARM, INC.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. CEVA SANTÉ ANIMALE S.A.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. DR. E. GRAEUB AG

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. A X IENCE SAS

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. ELI LILLY AND COMPANY

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty

Atipamezole Market by Application (Anti-Sedative and Others) and Route of Administration (Intravenous, Intramuscular, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025